Search results
Showing 6931 to 6945 of 8904 results
We have moved Diagnostics guidance 18 to become HealthTech guidance 386. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)
This guideline has been updated and replaced by NICE guideline NG131.
Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)
Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.
SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (DG20)
We have moved Diagnostics guidance 20 to become HealthTech guidance 400. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 43 to become HealthTech guidance 571. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)
We have moved Diagnostics guidance 45 to become HealthTech guidance 610. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)
We have moved Diagnostics guidance 41 to become HealthTech guidance 553. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (DG46)
We have moved Diagnostics guidance 46 to become HealthTech guidance 611. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (DG48)
We have moved Diagnostics guidance 48 to become HealthTech guidance 682. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 5 to become HealthTech guidance 291. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 51 to become HealthTech guidance 657. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
PLGF-based testing to help diagnose suspected preterm pre-eclampsia (DG49)
We have moved Diagnostics guidance 49 to become HealthTech guidance 630. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)
We have moved Diagnostics guidance 50 to become HealthTech guidance 655. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 47 to become HealthTech guidance 619. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 52 to become HealthTech guidance 677. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.